.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EF03_Abemaciclib.Abemaciclib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EF03_Abemaciclib.Abemaciclib| name: | Abemaciclib |
| ATC code: | L01EF03 | route: | oral |
| n-compartments | 2 |
Abemaciclib is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It is used mainly in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, typically in combination with endocrine therapy. Abemaciclib is approved for clinical use.
Pharmacokinetic parameters derived from adult patients with solid tumors and healthy subjects after oral administration under fed and fasting conditions.
Chigutsa, E, et al., & Turner, PK (2020). Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics. CPT: pharmacometrics & systems pharmacology 9(9) 523–533. DOI:10.1002/psp4.12544 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32683787
Tate, SC, et al., & Cronier, DM (2018). A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients. Clinical pharmacokinetics 57(3) 335–344. DOI:10.1007/s40262-017-0559-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28540640
Zhang, J, et al., & Hu, X (2021). A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers. Targeted oncology 16(2) 177–187. DOI:10.1007/s11523-020-00789-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33492568